Pharmaceutical and Immunological Evaluation of Cholera Toxin A1 Subunit as an Adjuvant of Hepatitis B Vaccine Microneedles
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE: For successful delivery of a solid vaccine formulation into the skin using microneedles, the solubility of an adjuvant should be considered because the decrease in the dissolution rate by the addition of adjuvant decreases the delivery efficiency of the vaccine.
METHODS: In this study, cholera toxin A subunit 1 (CTA1) was examined as an adjuvant to Hepatitis B vaccine (HBV) microneedles because of its good water solubility, improved safety, and positive effect as shown in intramuscular administration of a liquid vaccine.
RESULTS: All solid formulations with CTA 1 dissolved in in vivo mouse skin within 30 min, and they were successfully delivered into the skin. In experiments with mice, the addition of CTA1 led to improved IgG immune response compared to the use of an aluminum hydroxide-based formulation and intramuscular administration of HBV. In addition, CTA1 induced CD8 + T cell response as much as in which the aluminum hydroxide-based formulation induced.
CONCLUSIONS: CTA1 is an adjuvant that satisfies both the delivery efficiency and the immunological characteristics required for vaccine microneedles. CTA1 will be used as a potential adjuvant through vaccine microneedles.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Pharmaceutical research - 40(2023), 12 vom: 27. Dez., Seite 3059-3071 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Jong-Chan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 16.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11095-023-03623-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364067357 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364067357 | ||
| 003 | DE-627 | ||
| 005 | 20240117232007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-023-03623-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM364067357 | ||
| 035 | |a (NLM)37914841 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Jong-Chan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical and Immunological Evaluation of Cholera Toxin A1 Subunit as an Adjuvant of Hepatitis B Vaccine Microneedles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE: For successful delivery of a solid vaccine formulation into the skin using microneedles, the solubility of an adjuvant should be considered because the decrease in the dissolution rate by the addition of adjuvant decreases the delivery efficiency of the vaccine | ||
| 520 | |a METHODS: In this study, cholera toxin A subunit 1 (CTA1) was examined as an adjuvant to Hepatitis B vaccine (HBV) microneedles because of its good water solubility, improved safety, and positive effect as shown in intramuscular administration of a liquid vaccine | ||
| 520 | |a RESULTS: All solid formulations with CTA 1 dissolved in in vivo mouse skin within 30 min, and they were successfully delivered into the skin. In experiments with mice, the addition of CTA1 led to improved IgG immune response compared to the use of an aluminum hydroxide-based formulation and intramuscular administration of HBV. In addition, CTA1 induced CD8 + T cell response as much as in which the aluminum hydroxide-based formulation induced | ||
| 520 | |a CONCLUSIONS: CTA1 is an adjuvant that satisfies both the delivery efficiency and the immunological characteristics required for vaccine microneedles. CTA1 will be used as a potential adjuvant through vaccine microneedles | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTA1 | |
| 650 | 4 | |a dissolution rate | |
| 650 | 4 | |a hepatitis B vaccine | |
| 650 | 4 | |a immunological efficacy | |
| 650 | 4 | |a microneedles | |
| 650 | 7 | |a Cholera Toxin |2 NLM | |
| 650 | 7 | |a 9012-63-9 |2 NLM | |
| 650 | 7 | |a Hepatitis B Vaccines |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Aluminum Hydroxide |2 NLM | |
| 650 | 7 | |a 5QB0T2IUN0 |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 700 | 1 | |a Choi, Jung-Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hayan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Eunji |e verfasserin |4 aut | |
| 700 | 1 | |a Noh, Shinyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ji-Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Moon-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Manki |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jung-Hwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d 1984 |g 40(2023), 12 vom: 27. Dez., Seite 3059-3071 |w (DE-627)NLM012597236 |x 1573-904X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:12 |g day:27 |g month:12 |g pages:3059-3071 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11095-023-03623-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 12 |b 27 |c 12 |h 3059-3071 | ||